Please login to the form below

Not currently logged in
Email:
Password:

pancreatic adenocarcinoma.

This page shows the latest pancreatic adenocarcinoma. news and features for those working in and with pharma, biotech and healthcare.

Merus makes case for bispecific antibody in specific cancer gene fusion

Merus makes case for bispecific antibody in specific cancer gene fusion

assessment. The three patients are currently remaining on treatment. The data also showed that the experimental therapy worked across cancer types – patient one and two had pancreatic ductal adenocarcinoma, with the ... It is notable that two of the

Latest news

  • EU green light for Novartis' skin cancer therapy EU green light for Novartis' skin cancer therapy

    Other studies of the drug are ongoing in prostate cancer, pancreatic adenocarcinoma, ovarian cancer, non-small cell lung cancer and triple-negative breast cancer, as well as haematological malignancies such as

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • Merck KGaA starts third phase III trial for cancer hope TH-302 Merck KGaA starts third phase III trial for cancer hope TH-302

    Merck KGaA has started a phase III trial of its novel cancer candidate TH-302 in patients with locally advanced or metastatic pancreatic adenocarcinoma. ... The new phase III trial -called MAESTRO - aims to enrol 600 patients and will compare TH-302 plus

  • RNA interference rebirth RNA interference rebirth

    pancreatic adenocarcinoma. I. ALN-VSP. Alnylam. VEGF/KSP. liver cancers. I. ALN-TTR. Alnylam.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    Take the pancreatic adenocarcinoma scenario for example, if the drug developers had targeted their research in Europe instead of the USA, one could have found a much more favourable research environment. ... 7)  EpiomicTM Patient Segmentation Database,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....